Cytotec shortage: What providers and prescribers need to know in 2026

Cytotec Supply in 2026: A Provider Perspective

If your patients are reporting difficulty filling Misoprostol prescriptions, they're not alone. The Cytotec (Misoprostol) supply situation in 2026 continues to be characterized by intermittent availability disruptions, driven by manufacturing constraints, demand volatility, and an evolving regulatory landscape. This guide covers what prescribers and clinical teams need to know to manage patient care when Misoprostol supply is unreliable.

Understanding the Current Supply Landscape

Misoprostol—a synthetic prostaglandin E1 analog FDA-approved for the prevention of NSAID-induced gastric ulcers—is produced by a small number of generic manufacturers. This concentrated manufacturing base creates vulnerability: when even one producer experiences a disruption, the entire market feels the impact.

Key supply drivers in 2026 include:

• Manufacturing consolidation: Few companies produce Misoprostol, and thin margins on generic drugs discourage maintaining large safety stocks.
• Demand-side volatility: Post-Dobbs demand shifts continue to affect stocking patterns. Demand surges in states with broader access and reduced stocking in restrictive states create an uneven national picture.
• Distributor allocation: During tight supply, wholesalers may allocate limited quantities per pharmacy, leaving some locations consistently under-stocked.
• State-level regulatory friction: Varying state laws regarding Misoprostol dispensing create compliance concerns that affect pharmacy willingness to stock the drug.

Clinical Implications for Your Practice

Gastroenterology and Rheumatology

For patients on long-term NSAID therapy who need gastroprotection, Misoprostol remains the only FDA-approved prostaglandin analog for this indication. However, evidence supports proton pump inhibitors (PPIs) as comparably effective alternatives:

• Omeprazole 20 mg daily: The OMNIUM trial demonstrated comparable efficacy to Misoprostol for gastric ulcer prevention, with better tolerability.
• Lansoprazole 15-30 mg daily: Effective alternative, studied head-to-head against Misoprostol.
• Esomeprazole, Pantoprazole, Rabeprazole: Class-effect alternatives when first-line PPIs aren't suitable.

For patients already stable on Misoprostol, switching to a PPI during supply disruptions is a clinically sound approach. Document the shortage as the reason for the change.

Obstetrics and Gynecology

Supply disruptions have particular urgency in OB/GYN settings where Misoprostol is used off-label for:

• Cervical ripening and labor induction
• Medical management of early pregnancy loss
• Medication abortion (in combination with mifepristone)
• Postpartum hemorrhage treatment

For these indications, alternatives include dinoprostone (Cervidil/Prepidil) for cervical ripening and oxytocin for labor induction, though these have different efficacy profiles and administration requirements. Institutional pharmacy departments should be aware of supply trends and maintain safety stock for time-sensitive indications.

Helping Your Patients Navigate Access

When a patient reports they can't fill their Misoprostol prescription, consider the following:

1. Include the Diagnosis on the Prescription

In states where Misoprostol dispensing triggers additional pharmacy verification, including the ICD-10 diagnosis code on the prescription can expedite filling. This clarifies the indication and reduces pharmacy hesitation.

2. Direct Patients to MedFinder

MedFinder for Providers offers tools to help patients locate pharmacies with Cytotec in stock. Recommending this resource can reduce the back-and-forth calls between your office and pharmacies.

3. Consider Mail-Order Options

Mail-order pharmacies often have better access to medications experiencing local supply disruptions. Patients with stable, ongoing prescriptions may benefit from switching to a mail-order pharmacy for more reliable access.

4. Plan for Therapeutic Substitution

Have a backup plan documented in the patient's chart. For GI patients, a standing order or protocol for switching to a PPI during Misoprostol shortages can streamline care and reduce delays.

5. Communicate Proactively

If you serve a large population of patients on Misoprostol, consider proactive communication (through your patient portal or office staff) when you become aware of supply issues. This gives patients time to plan rather than discovering the problem at the pharmacy counter.

Prescribing Considerations

• Dosage flexibility: Misoprostol is available in 100 mcg and 200 mcg tablets. If one strength is unavailable, the other may be in stock. Adjust the prescription accordingly.
• Quantity optimization: Consider prescribing 90-day supplies when appropriate to reduce refill frequency and exposure to intermittent shortages.
• Boxed warning compliance: Remember that Misoprostol carries a boxed warning regarding use in pregnant women. Ensure that women of childbearing potential have a documented negative pregnancy test, are on effective contraception, and have received written warnings per FDA labeling requirements.

Reporting and Monitoring

Providers who observe significant supply gaps should report them through the FDA Drug Shortage Reporting Portal. These reports help the FDA track real-world availability and may prompt intervention with manufacturers.

For additional context on what patients are experiencing, see our patient-facing articles on the Cytotec shortage and why Cytotec is hard to find. For a provider-specific guide on helping patients access the drug, see How to help your patients find Cytotec in stock.